Published in Women's Health Weekly, January 12th, 2006
"Signal transduction pathways associated with cancer progression and chemotherapeutic resistance are being investigated as molecular targets for chemotherapy. The P13K pathway has been found to be frequently amplified and have increased activity in ovarian cancer," wrote S.D. Westfall and colleagues, Washington State University.
"The current study investigates the efficacy of an antagonist of P13K, LY294002, in inhibiting ovarian cancer cell growth...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.